Will initial consultation patterns among undiagnosed cancer patients be the same after this COVID-19 pandemic? Experiences from the 2011 triple disaster in Fukushima, Japan

Akihiko Ozaki¹, Toyoaki Sawano², Hiroaki Saito³, Tetsuya Tanimoto⁴, Masaharu Tsubokura⁵

¹Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, Japan

²Department of Surgery, Sendai City Medical Center, Sendai Open Hospital, Sendai, Miyagi, Japan

³Department of Gastroenterology, Sendai Kousei Hospital, Sendai, Miyagi, Japan

⁴Medical Governance Research Institute, Minato-ku, Tokyo

⁵Department of Radiation Health Management, Fukushima Medical University, Fukushima, Japan

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19), first broke out in Wuhan, China in December 2019, and has spread out worldwide causing a global pandemic. As cancer patients are deemed to be a high-risk population of COVID-19, the effect of COVID-19 on the cancer population and their treatment has already been widely discussed across various media and academic journals [1-3]. Briefly, it is important not only to protect cancer patients from SARS-CoV-2 infection, but also to continuously provide appropriate and timely care depending on the urgency of their conditions. However, such discussions have primarily focused on patients already diagnosed with cancer – patients waiting for treatment inception, patients already receiving treatment, and survivors in surveillance after treatment, and the short-term health effects among these populations. In contrast, little has been said regarding undiagnosed cancer patients (ie, before cancer diagnosis) and/or their long-term health consequences.

When considering undiagnosed cancer patients during the COVID-19 pandemic, we believe that our experiences in Fukushima would help further develop our discussions. We have been involved in care and research on cancer patients in Fukushima following the 2011 triple disaster (earthquake, tsunami, and

Prevailing discussions with regard to cancer in the COVID-19 pandemic have primarily focused on patients already diagnosed with cancer and short-term health effects among these populations, but arguments on undiagnosed cancer patients (ie, before cancer diagnosis) and/or their long-term health consequences are similarly important. a following the 2011 triple disaster (earthquake, tsunami, and nuclear accident) of the Great East Japan Earthquake, witnessing how long-term health effects have developed since the onset of this complex disaster. Arguably, the radiation disaster and the pandemic would indeed be seemingly different; however, COVID-19 is caused by an intangible pathogen with relatively unknown effects, which has some similarities with radioactive substances in their influence on human behavior as both would make people isolate themselves from others. For example, in the coastal area of Fukushima, the fear of radiation exposure has persistently prevented local residents from consuming locally grown food for more than five years after the disaster, although the air radiation dose rate was demonstrated to be at an One lesson learned from the 2011 triple disaster in Fukushima is that a proportion of undiagnosed symptomatic cancer patients who would delay seeking healthcare was significantly increased for fear of radiation exposure, and this experience should be shared among healthcare professionals, public health practitioners, and policy makers globally, since the COVID-19 pandemic can cause similar situation for fear of contagion. acceptable level just a few years following the disaster [4]. This means that people may change their behavioral patterns for much longer than reasonably anticipated.

In the wake of the triple disaster, the most striking observation regarding cancer was an increase in the proportion of undiagnosed symptomatic breast cancer patients in the affected areas who delayed seeking initial medical consultation, and this situation has persisted for over five years after the disaster [5]. More concretely, 18.0% of the post-disaster patients delayed their initial medical consultation for 12 months or longer, while such a delay had occurred only 4.1% of the pre-disaster population (age adjusted risk ratio post- vs predisaster: 4.49, 95% confidence interval 1.73-11.65) [5]. Fur-

ther, there is anecdotal evidence that the similar delay occurred among undiagnosed symptomatic colorectal cancer patients in the post-disaster period [6]. The most likely explanation for this is a decreased interest in seeking medical consultation for apparently non-urgent symptoms, as suggested by our in-depth interviews with some of the patients [6,7]. What should be noted is that these post-disaster changes in behavioral patterns among undiagnosed symptomatic cancer patients occurred although the local cancer care had been restored to enable the post-disaster cancer patients to receive timely initial treatment, at least six months after the disaster [8].

Similarly, when the "New Normal" is established during the COVID-19 pandemic, we are concerned that initial medical consultation among undiagnosed symptomatic cancer patients could be delayed because of the hesitance to request medical consultation promptly for fear of contracting COVID-19. Given that the current pandemic is projected to last until 2022 [9], and that this projection has been repeatedly disseminated via various media outlets, baseline motivation for medical consultation for non-urgent symptoms may decline for the next several years because of fear of infection. The same may be true with cancer screening for asymptomatic populations, given that the priority of such preventive measures may further decline in the same context.



Photo: from the Jyoban Hospital of Tokiwa Founation, used with permission.

Naturally since its outbreak, COVID-19 has drawn huge attention to its direct health effects and interrupted care for other conditions including cancer, as originally seen in the 2011 triple disaster in Fukushima. However, once its death toll declines and people become accustomed to the New Normal soon, an interest in the COVID-19 and its related health problems would potentially diminish all in academic, mass media and general communities, as seen following the triple disaster. In this regard, health care professionals, public health practitioners, and policy makers should have a long-term perspective to reveal and mitigate potentially diverse and long-term health effects on cancer caused by the COVID-19 pandemic. To this end, appropriate designing of researches to clarify these health issues and relevant logistics enabling such researches are both essential. In the meantime, it is important to enhance awareness of signs and symptoms suggestive of cancer among the general public and to motivate them to regularly participate in cancer screening programs and/or do appropriate self-examination and self-care. Both in research and clinical practice, crosssectional and longitudinal collaborations involving multiple stakeholders are critical to protect health and well-beings of cancer patients in the long term. Specifically, a close attention should be paid to whether a proportion of undiagnosed

symptomatic cancer patients that delay seeking health care would be increased for fear of contracting COVID-19, a lesson learned from the 2011 triple disaster that should be shared globally.

Funding: None.

Authorship contributions: AO wrote the manuscript. AO and MT contributed to conception and design of the study. All authors contributed to critical revision of the paper and approved the final manuscript.

Competing interests: Akihiko Ozaki and Tetsuya Tanimoto receive personal fees from MNES Inc and Bionics co., Ltd., outside the submitted work. The authors completed the ICMJE Unified Competing Interest form (available upon request from the corresponding author), and declare no further conflicts of interest.

- 1 Schrag D, Hershman DL, Basch E. Oncology practice during the COVID-19 pandemic. JAMA. 2020. Online ahead of print. Medline:32282023 doi:10.1001/jama.2020.6236
- **2** Spicer J, Chamberlain C, Papa S. Provision of cancer care during the COVID-19 pandemic. Nat Rev Clin Oncol. 2020;17:329-31. Medline:32296166 doi:10.1038/s41571-020-0370-6
- 3 Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31:894-901. Medline:32224151 doi:10.1016/j.annonc.2020.03.296
- 4 Takebayashi Y, Mukrami M, Nomura S, Oikawa T, Tsubokura M. The trajectories of local food avoidance after the Fukushima Daiichi nuclear plant disaster: A five-year prospective cohort study. Int J Disast Ris Re. 2020;46:101513. doi:10.1016/j.ijdrr.2020.101513
- 5 Ozaki A, Nomura S, Leppold C, Tsubokura M, Tanimoto T, Yokota T, et al. Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study. BMC Cancer. 2017;17:423. Medline:28629330 doi:10.1186/s12885-017-3412-4
- **6** Ozaki A, Leppold C, Sawano T, Tsubokura M, Tsukada M, Tanimoto T, et al. Social isolation and cancer management advanced rectal cancer with patient delay following the 2011 triple disaster in Fukushima, Japan: a case report. J Med Case Rep. 2017;11:138. Medline:28506309 doi:10.1186/s13256-017-1306-3
- 7 Ozaki A, Leppold C, Tsubokura M, Tanimoto T, Saji S, Kato S, et al. Social isolation and cancer management after the 2011 triple disaster in Fukushima, Japan: A case report of breast cancer with patient and provider delay. Medicine (Baltimore). 2016;95:e4027. Medline:27368025 doi:10.1097/MD.00000000004027
- 8 Ozaki A, Nomura S, Leppold C, Tsubokura M, Sawano T, Tsukada M, et al. Breast cancer provider interval length in Fukushima, Japan, after the 2011 triple disaster: a long-term retrospective study. Clin Breast Cancer. 2020;20:e127-50. Medline:31980405 doi:10.1016/j.clbc.2019.07.008
- 9 Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368:860-8. Medline:32291278 doi:10.1126/science.abb5793

Correspondence to: Akihiko Ozaki Department of Breast Surgery Jyoban Hospital of Tokiwa Foundation 57 Kaminodai Jyoban-Kamiyunaga-Yamachi Iwaki Fukushima Japan aozaki-tky@umin.ac.jp